T. Rowe Price Investment Management’s 10x Genomics TXG Stock Holding History

T. Rowe Price Investment Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.2M	Sell	1,279,382 -121	-0%	-$2.42K	0.02%	431
2025 Q4	$20.9M	Sell	1,279,503 -62,920	-5%	-$950K	0.01%	486
2025 Q3	$15.7M	Buy	1,342,423 +364,738	+37%	+$4.76M	0.01%	533
2025 Q2	$11.3M	Buy	+977,685	New	+$8.91M	0.01%	549
2024 Q4	–	Sell	-2,161,775	Closed	-$48.8M	–	674
2024 Q3	$48.8M	Sell	2,161,775 -1,204	-0.1%	-$24.9K	0.03%	409
2024 Q2	$42.1M	Sell	2,162,979 -41,451	-2%	-$1.09M	0.03%	411
2024 Q1	$82.7M	Buy	2,204,430 +1,063,386	+93%	+$46.7M	0.05%	316
2023 Q4	$63.9M	Buy	1,141,044 +144,379	+14%	+$6.28M	0.04%	353
2023 Q3	$41.1M	Hold	996,665	–	–	0.03%	392
2023 Q2	$55.7M	Sell	996,665 -29,296	-3%	-$1.59M	0.04%	363
2023 Q1	$57.2M	Buy	+1,025,961	New	+$47.9M	0.04%	347

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management's TXG Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its 10x Genomics (TXG) stake by 0.01% in Q1 2026, selling an estimated $2.42K and leaving 1,279,382 shares worth $27.2M. The position accounts for 0.02% of the portfolio, ranked #431.

T. Rowe Price Investment Management first reported a position in TXG in Q1 2023 and has held it in 11 quarters since. The position peaked at $82.7M in Q1 2024. 330 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

T. Rowe Price Investment Management held 1,279,382 shares of 10x Genomics worth $27.2M as of Q1 2026.
T. Rowe Price Investment Management sold 121 10x Genomics shares in Q1 2026, an estimated $2.42K.
10x Genomics made up 0.02% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #431 holding.
T. Rowe Price Investment Management first reported a position in 10x Genomics in Q1 2023 and has held it in 11 quarters since.
T. Rowe Price Investment Management's 10x Genomics position peaked at $82.7M in Q1 2024.
330 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.